Could GLP-1 Therapies Drive Growth for Eli Lilly and Novo Nordisk Stocks?
This clinical trial could pave the way for even larger markets
Novo Nordisk's blockbuster drug Ozempic is widely known for being effective at controlling type 2 diabetes. Novo also makes Wegovy for treating obesity, which is the same molecule (called semaglutide) as Ozempic. Likewise, Eli Lilly's drugs Mounjaro and Zepbound are the same molecule (tirzepatide), and they are indicated for the same two conditions.
Diabetes and obesity markets
- Diabetes market: Mounjaro brought in more than $2.2 billion in sales for Eli Lilly in Q4 alone.
- Obesity market: Ozempic drove growth of about 42% in Novo's segment, bringing it to more than $31.2 billion in total for 2023.
According to analysts at J.P. Morgan, the GLP-1 therapies market could reach $71 billion by 2032.
Potential for Parkinson's treatment
The New England Journal of Medicine published promising results from a phase 2 trial on Parkinson's patients treated with a GLP-1 targeted molecule. The study suggests a positive impact on motor symptoms, hinting at future Parkinson's treatments.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.